Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

BACKGROUND: Empagliflozin (empa), a selective sodium–glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk independent of glycemic control. The cardiovascular protective effect of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sin-Hee, Farooq, Muhammad Akmal, Gaertner, Sébastien, Bruckert, Christophe, Qureshi, Abdul Wahid, Lee, Hyun-Ho, Benrahla, Djamel, Pollet, Brigitte, Stephan, Dominique, Ohlmann, Patrick, Lessinger, Jean-Marc, Mayoux, Eric, Auger, Cyril, Morel, Olivier, Schini-Kerth, Valérie B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026972/
https://www.ncbi.nlm.nih.gov/pubmed/32070346
http://dx.doi.org/10.1186/s12933-020-00997-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026972/
https://www.ncbi.nlm.nih.gov/pubmed/32070346
http://dx.doi.org/10.1186/s12933-020-00997-7

Ejemplares similares